Cancer Research

#Biologics #Drug development #Drug discovery #Oncology #Therapeutics

International consortium awarded grant for first-in-class metastatic cancer treatment

ONA Therapeutics, Absolute Antibody and RIC – three leading European companies in the biotech landscape – have been awarded a Eurostars grant for a two-year project that will develop a proprietary biological drug with a unique mode of action for the treatment of various types of metastatic cancers. Taking the… Read More

#Cancer Research #News

#AI / data analytics / healthtech / informatics #Antibodies #Biotechnology #Cancer research #Drug development #Oncology

AI-driven precision medicine for development of HMBD-001 in HER3-driven cancers

Hummingbird Bioscience, a clinical-stage biotech company focused on developing revolutionary therapies for hard-to-drug targets, is collaborating with Tempus, an expert in artificial intelligence and precision medicine. This will drive the development of Hummingbird’s lead clinical program, HMBD-001, as it advances into clinical trials in HER3-driven cancers, including those that harbour… Read More

#Cancer Research #News

#CAR-T #Oncology #Therapeutics

CAR T-cell therapy highly effective in patients with high-risk non-Hodgkin lymphoma

A CAR T-cell therapy known as axicabtagene ciloleucel (axi-cel) drove cancer cells to undetectable levels in nearly 80% of patients with advanced non-Hodgkin lymphoma (NHL) in a Phase III clinical trial, Dana-Farber Cancer Institute investigators report at the virtual 62nd American Society of Hematology (ASH) Annual Meeting. While… Read More

#Cancer Research #News #Videos

#Cellular & Molecular biology #Oncology

Scientists use geometry to track cell migrations with potential impact for cancer research

https://www.ddw-online.com/wp-content/uploads/2020/12/collage.mp4   Cells are constantly moving throughout our bodies, performing functions crucial to tissue development, immune responses and general wellbeing. This locomotion—an essential feature of biological processes, both normal and pathological—is guided by chemical cues long studied by scientists interested in cellular migration. But a team of physicists and… Read More

#Cancer Research #Editor's Choice #News #Videos

#Biotechnology #Oncology #Therapeutics

STORM Therapeutics uses Evotec platform to push oncology project towards clinical studies

STORM Therapeutics will use INDiGO, Evotec’s integrated, accelerated IND-enabling platform, to progress its STC-15 towards an IND application in 2021. STORM, a biotechnology company focused on the discovery and development of small molecule therapies modulating RNA epigenetics, has selected STC-15 as a first-in-class development candidate. STORM discovered STC-15, an orally… Read More

#Cancer Research #News

#Biopharmaceuticals #Oncology #Therapeutics

Merck’s acquisition of VelosBio will boost oncology push

Merck (known as MSD outside the United States and Canada), is paying  $2.75 billion for VelosBio, a clinical-stage biopharmaceutical company committed to developing first-in-class cancer therapies targeting receptor tyrosine kinase-like orphan receptor 1 (ROR1). VelosBio’s lead investigational candidate is VLS-101, an antibody-drug conjugate (ADC) targeting ROR1 that is currently being… Read More

#Cancer Research #News

#Biotechnology #Drug discovery #Drug targets #Hit identification #Immunotherapy #Oncology

Partnership will progress targeted cancer immune therapy drug discovery

APEIRON Biologics, a biotech company developing breakthrough therapies to treat cancer and respiratory conditions, has selected Domainex to provide integrated lead optimisation services in order to advance the development of inhibitors for the E3 ubiquitin ligase Cbl-b through small molecule drug discovery. Under the terms of the agreement, Domainex, an… Read More

#Cancer Research #News

#Cancer research #Immunotherapy

Scientists engineer new cancer immunotherapy to train immune system in cancer fight

A new type of cancer immunotherapy developed at the Icahn School of Medicine at Mount Sinai trains the innate immune system to help it eliminate tumour cells through the use of nanobiologics, tiny materials bioengineered from natural molecules that are paired with a therapeutic component, according to a study published… Read More

#Cancer Research #News #Trending News

#Cancer research #Oncology

Cancer Research UK collaboration will identify oncology innovation

The national programme, to develop and progress start-up oncology projects, is being launched by Bruntwood SciTech at Alderley Park with funding from Innovate UK and Cancer Research UK A collaboration of global pharmaceutical and healthcare companies, research institutions and public bodies will identify oncology innovations and leverage their combined insight… Read More

#Cancer Research #Editor's Choice #News